-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c ; Offers Guidance
-
-
-
-
-
-
-
Amneal receives tentative FDA approval for generic asthma inhaler
-
-
-
-
-
-
-
Goldman Sachs Starts Amneal Pharmaceuticals (AMRX) at Neutral
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Announces Expanded Coverage for CREXONT to Enhance Access for Parkinson’s Disease Patients in the U.S.
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler
-
-
-
-
-
-
-
JPMorgan Upgrades Amneal Pharmaceuticals (AMRX) to Neutral
-
-
-
-
-
413,433 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

